XCUR

Exicure Announces Board and Committee Changes

Exicure reshuffles board with independent directors as strategic review proceeds

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Exicure announced June 30, 2026 governance changes, including Ham&#039;s resignation and appointments of Jin Young Go and Eui Seok Han, expanding the board to six while preserving Nasdaq independence. The Audit Committee remains; a new Compensation Committee was formed. The company, restructuring and suspending clinical activities, is pursuing strategic alternatives to maximize stockholder value.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Ham resigns from Exicure board; Jin Young Go and Eui Seok Han appointed.</li><li>Board expands to six; Han qualifies as independent under Nasdaq rules.</li><li>Audit Committee remains; a new Compensation Committee is formed.</li><li>Company pursuing strategic alternatives after restructuring; clinical activities suspended.</li><li>8-K filing to disclose further details and timeline.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Exicure, Inc. (XCUR)</strong>: Governance changes and board reshuffle may influence strategic direction and shareholder value.</li><li><strong>Nasdaq, Inc. (NDAQ)</strong>: Independence standards referenced; governance credibility tied to Nasdaq listing rules.</li><li><strong>Jung Kyu Ham (N/A)</strong>: Resigned from the board; vacancy created.</li><li><strong>Jin Young Go (N/A)</strong>: Appointed Class III director; joins board.</li><li><strong>Eui Seok Han (N/A)</strong>: Appointed Class III director; independent; to chair Compensation Committee.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. The governance changes reflect strategic recalibration and potential value exploration, standard for a biotech with restructuring; outcomes hinge on subsequent strategic steps and disclosures.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Nasdaq independence reaffirmed, supporting governance credibility and sentiment.</li><li>Board expansion and new independent director could shift strategic priorities.</li><li>No near-term clinical catalysts; focus on strategic alternatives and disclosures.</li><li>Upcoming 8-K filing may refine timelines and governance details.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Resignation of Jung Kyu Ham as director effective June 30, 2026.</li><li>Appointment of Jin Young Go as Class III director effective June 30, 2026.</li><li>Appointment of Eui Seok Han as Class III director, independent per Nasdaq rules.</li><li>Board size increased from five to six directors.</li><li>Audit Committee remains: Yoon Tae Han (Chair), Dongho Lee, Gyeong Seog Cheon.</li><li>Compensation Committee established: Eui Seok Han (Chair) and Dongho Lee.</li><li>8-K to be filed with the SEC for additional information.</li><li>Company suspended clinical and development activities; pursuing strategic alternatives.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Neutral near-term; potential upside if strategic review yields value-enhancing outcomes within 3–12 months.</p>
  </section>
</section>


<article>
  <section>
    <h2>Exicure Announces Board and Committee Changes</h2>
    <p>WILMINGTON, Del., June  30, 2026  (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/XCUR">XCUR</a>) (&#34;Exicure&#34; or the &#34;Company&#34;) today announced changes to its Board of Directors and Board committees following actions approved by the Company&#39;s Board of Directors at its special meeting held on June 24, 2026.</p>
    <p>The Company&#39;s Board of Directors accepted the resignation of Jung Kyu Ham as a director, effective June 30, 2026.</p>
    <p>The Board also appointed Jin Young Go as a Class III director to fill the vacancy created by Mr. Ham&#39;s resignation. In addition, the Board approved an increase in the size of the Board from five to six directors and appointed Eui Seok Han as a Class III director to fill the newly created directorship. Both appointments are effective June 30, 2026.</p>
    <p>Following a review of the applicable Nasdaq independence standards, the Board determined that Eui Seok Han qualifies as an independent director under the Nasdaq Listing Rules. Following these changes, the Company continues to satisfy the Nasdaq requirement that a majority of its Board consist of independent directors.</p>
    <p>The Board also confirmed the composition of its Audit Committee, which will continue to consist of Yoon Tae Han (Chair), Dongho Lee and Gyeong Seog Cheon. In addition, the Board established a Compensation Committee comprised of Eui Seok Han (Chair) and Dongho Lee, effective June 30, 2026.</p>
    <p>Additional information regarding these matters will be included in the Company&#39;s Current Report on Form 8-K to be filed with the U.S. Securities and Exchange Commission.</p>
    <ul>
      <li><strong>Board size change:</strong> increase from <strong>five</strong> to <strong>six</strong> directors – <em>20% increase</em></li>
      <li><strong>Resignation:</strong> Jung Kyu Ham, effective <strong>June 30, 2026</strong></li>
      <li><strong>New independent director:</strong> Eui Seok Han, qualified as independent under Nasdaq Listing Rules</li>
      <li><strong>New Class III director appointee:</strong> Jin Young Go</li>
      <li><strong>Audit Committee:</strong> Yoon Tae Han (Chair), Dongho Lee, Gyeong Seog Cheon</li>
      <li><strong>Compensation Committee:</strong> Eui Seok Han (Chair), Dongho Lee</li>
    </ul>
  </section>

  <section>
    <h3>About Exicure, Inc.</h3>
    <p>Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/XCUR">XCUR</a>) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value. In January 2025, it acquired a clinical-stage biotechnology company developing therapeutics for hematologic diseases. The Company&#39;s lead program is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy.</p>
  </section>

  <section>
    <h3>Forward-Looking Statements</h3>
    <p>This press release contains forward-looking statements within the meaning of applicable federal securities laws, including statements regarding the Company&#39;s corporate governance, Board composition and strategic direction. Forward-looking statements are based on management&#39;s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. The Company undertakes no obligation to update any forward-looking statements except as required by applicable law.</p>
  </section>

  <section>
    <h3>Media Contact</h3>
    <p><strong>Media Contact</strong></p>
    <p>Exicure, Inc.</p>
    <p>pr@exicuretx.com</p>
  </section>

  <section>
    <p><img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTc1NDcyMCM3Njg0NjY5IzIwMjAyMzU="></p>
    <p><br><img alt="" src="https://ml.globenewswire.com/media/NDRiYzYxOWEtN2Y5Zi00NzkwLThlNjAtZTIyNDVkMWQ2ZDZmLTEwMzE4MDctMjAyNi0wNi0zMC1lbg==/tiny/Exicure-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></p>
    <p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/3a5f958d-422c-4a97-a96d-cf06f640b587"><img src="https://ml.globenewswire.com/media/3a5f958d-422c-4a97-a96d-cf06f640b587/small/exicure-logo-final-full-color-072515-png.png" border="0" width="150" height="37" alt="Primary Logo"></img></a></p>
  </section>
</article>

Exicure announced June 30, 2026 governance changes, including Ham's resignation and appointments of Jin Young Go and Eui Seok Han, expanding the board to six while preserving Nasdaq independence. The Audit Committee remains; a new Compensation Committee was formed. The company, restructuring and suspending clinical activities, is pursuing strategic alternatives to maximize stockholder value.

Exicure Announces Board and Committee Changes

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News